Deal Watch: AbbVie Cancels Shire Buyout, Blaming U.S. Tax Policy Revisions
Actavis potentially bolsters its GI franchise by optioning rights to peptide ghrelin agonist relamorelin and also the opportunity to buy out Rhythm Health. Meanwhile, Celgene increases its stake in Sutro and Janssen joins the Ebola fight.
You may also be interested in...
US Chamber of Commerce wants court to eliminate IRS rule that blocked Pfizer's acquisition of Allergan; AbbVie hit with second suit over its 2014 proposed acquisition of Shire.
Celgene Corp. has deepened its investment in antibody R&D, striking a collaboration with Sutro Biopharma to design and develop next-gen antibodies and to manufacture a proprietary Celgene candidate. Sutro gets cash, biobucks, and hi-profile validation of its multi-faceted non-cell antibody platform.
A regulatory filing for Vyjuvek in the US is targeted for the first half of 2022 following the positive results of a Phase III trial, positioning Krystal for its first commercial launch.